Video summarizing the recent work published by Xosé R. Bustelo’s group (Centro de Investigación del Cáncer) in Cell Reports in which they have demonstrated that mutations in RRAS2, a gene that encodes a RAS-like protein, behave as potent oncogenic drivers for a large spectrum of tumor types. In this work, they have also identified the mechanisms by which these mutations promote the generation of cancer cells and ways to eliminate them using specific anti-cancer drugs. In addition to the cancer field, these results are also of potential interest for other human diseases that contain RRAS2 mutations such as, for example, Noonan syndrome.
For more information, you can look at the publication in which these data have been published:
Title: A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors
Journal: Cell Rep 2022. 38 (11): 110522.
Authors: Isabel Fernández-Pisonero, Laura Clavaín , Javier Robles-Valero , L Francisco Lorenzo-Martín, Rubén Caloto , Blanca Nieto , Carmen García-Macías, Clara L Oeste , Manuel Sánchez-Martín, Antonio Abad , Alejandro Hortal , Dolores Caballero , Marcos González , Mercedes Dosil , Balbino Alarcón, and Xosé R Bustelo PMID: 35294890 DOI: 10.1016/j.celrep.2022.110522